Please login to the form below

Not currently logged in
Email:
Password:

brigatinib

This page shows the latest brigatinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer files third-gen ALK inhibitor for lung cancer

Pfizer files third-gen ALK inhibitor for lung cancer

Meanwhile another new entrant - Alunbrig (brigatinib) from Takeda - is also making headway after its first approval in 2017, making $13m by the end of the calendar year.

Latest news

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase ... Company acquisition. Rare diseases, option

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics